Vaccine composition against african swine fever virus
The vaccine composition of a chimeric antigen with ASFV p72 and CD154, potentially combined with B602L or p30, effectively addresses the ineffectiveness of existing ASF vaccines by inducing robust immune responses and preventing ASFV transmission, offering comprehensive protection against the virus.
Patent Information
- Application Number
- PCT/CU2024/050005
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-06
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current vaccines against African Swine Fever (ASF) virus lack effectiveness in providing lasting protection against different genotypes and are not capable of inhibiting horizontal and vertical transmission of the virus, posing significant challenges to the swine industry.
A protein subunit vaccine composition featuring a chimeric antigen with a fragment of the ASFV p72 protein fused to the extracellular segment of pig CD154, optionally combined with the chaperone protein B602L or the p30 protein, which is expressed in CHOK1 cells and formulated with Montanide, inducing a potent cellular and humoral immune response.
The vaccine formulation provides complete and early protection against ASFV infection, inhibiting both horizontal and vertical transmission of the virus, with enhanced immunogenicity and stability of the chimeric proteins, demonstrated by significant induction of neutralizing antibodies and CD8+ lymphocyte stimulation.
Smart Images

Figure CU2024050005_21112024_PF_FP_ABST
Abstract
Description
[0001] AFRICAN SWINE FEVER VIRUS VACCINE COMPOSITION
[0002] Field of technology
[0003] The present invention falls within the field of veterinary medicine, particularly for the prevention of infection by the African Swine Fever virus (ASFV) by immunizing pigs with vaccine formulations containing as an active pharmaceutical ingredient a fragment of the ASFV p72 protein fused to the extracellular segment of CD154 of pigs. The present invention also discloses the fusion of the 430 amino acid fragment of p72 with fragments of the ASFV chaperone protein B602L, in turn fused to the extracellular segment of CD154 of pigs, or the combination of the 324 amino acid chimeric antigen of the p72 protein and the extracellular segment of CD154 with different variants of the p30 protein of the same virus. Vaccine formulations comprising these antigens confer total horizontal and vertical protection against viral infection without any adverse effects occurring in the vaccinated organism.
[0004] State of the art
[0005] African swine fever (ASF) is a highly contagious hemorrhagic disease that affects domestic and wild pigs, causing serious economic and production losses to the swine industry (Biome, S. et al.; Virus Research 2020, 287: 198099). The disease was described since the beginning of the last century (Montgomery, R.; J. Comp. Pathol. 1921, 34: 159-191) and is endemic in sub-Saharan Africa. Transcontinental spread first occurred in Europe (Spain and Portugal) in 1957 and 1960, and from there to other European countries, South America and the Caribbean. With the exception of Sardinia, the disease was eradicated outside Africa by the mid-1990s. A second transcontinental spread to Georgia in the Caucasus occurred in 2007, with subsequent spread to neighboring Eastern European countries.Currently, ASFV is present in the Transcaucasus, parts of the Russian Federation and neighboring countries, including a region near the border with Mongolia (Sánchez-Cordón, PJ et al.; Vet. J. 2018, 233: 41-48). Over the past five years, the disease has spread to more than 50 countries, including China, which has the world's largest swine industry and whose pig population declined by 55% in 2019 (Carrillo C.; Vet Mex. 2020, 7(3): 1-21). Additionally, infected pigs have been detected in the Dominican Republic in recent months, posing a threat to the Caribbean and the Americas (Schambow, R. et al.; Front. Vet. Sci. 2022, 9).
[0006] ASF is caused by an icosahedral virus with a lipoprotein envelope (Sánchez-Vizcaíno, J.M. et al. Scie Direct. 2015, 152 (1): 9-21). This is the only member of the Asfarviridae family and the only known DNA arbovirus. The linear double-stranded DNA of this virus is approximately 170 to 193 kb in size and encodes between 150 and 165 proteins. Based on the variable regions at the C terminus of the viral capsid protein p72, ASFV has been classified into 24 genotypes present in Africa with different levels of virulence (Bao, J. et al.; Transbound Emerg Dis. 2019, 66 (3), 1167— 1176). Outside this endemic area, only genotype II of ASFV has been responsible for the spread of the virus since 2007 in Asia and Europe, and genotype I is endemic to Sardinia in Italy (Qu, H. et al., Virus Genes 2022, 58:77-87).There are other classifications for ASFV isolates that have identified eight serogroups based on the hemadsorption inhibition (HAI) assay (Malogolovkin, A., et al.; Emerg. Infect. Dis. 2015, 21 (2), 312-315). These serogroups in many cases do not correlate with the established genotypes based on the variable p72 sequence and therefore cross-protection against ASFV between these genogroups is not entirely clear (King K., et al.; Vaccine 2011, 29, 4593-600).
[0007] This viral particle is resistant to heat, putrefaction and pH and can be transmitted by different routes in addition to direct contact between infected pigs. Meat products and food waste contaminated with the virus are other transmission routes, as well as infestations of pigs with infected soft ticks of the genus Ornithodoros, where the virus can persist for up to 8 years (Olesen, AS et al.; Trans and Emerg Dis 2020, 67 (4): 1472-1484). Because it is so resistant to critical environmental conditions and can spread easily by different routes, this virus is mandatory to be notified to the World Organization for Animal Health (WHO). Since there are still no effective vaccines or treatments against ASF to date, timely and rapid diagnosis is essential for controlling disease transmission (Cubillos, C. et al. Virus Research 2013, 173 (1), 159-167).In this sense, government agencies, specialized scientific groups, consortia and international organizations such as the WHO and the Food and Agriculture Organization of the United Nations (FAO) have described the critical route that must be followed in the event of an ASF outbreak, which includes: diagnosis, slaughter of animals affected or exposed to the virus, strict quarantine, surveillance, biosecurity measures and restrictions on animal transport (Li, Z. et al., Life 2022, 12(8), 1255).
[0008] The complexity of the virus that causes ASF, the limited understanding of its virulence factors, and the antibody- and cell-mediated immune responses that must be enhanced for efficient immunization are several factors that have hampered the development of an effective vaccine against ASFV (Rock DL Vet. Microbiol. 2017, 206: 52-58). However, it is known that pigs that survive ASFV infection develop strong protective immunity and therefore a vaccine could be an effective method to combat the disease (Revilla, Y., et al.; Advanc Vir Research 2018, 100: 41-47). The inactivated vaccines developed to date have not shown a long-lasting protective effect in pigs (Cadenas-Fernández, E., et al.; Vaccines 2021, 9 (3), 242). The CD8 (+) lymphocyte population generated during infection appears to play an important role in protective immunity against ASFV (Takamatsu, HH, et al.; Virus Res 2013, 173 (1), 110-121). However, the changes in specific humoral and cellular immunity and their relative importance in infected pigs are not yet fully understood (Goatley, LC, et al.; Viruses 2022, 14 (7), 1487). Even with the use of live attenuated vaccines, it has not been possible to obtain a protective vaccine against all ASFV genotypes, and it is also difficult to establish the DIVA markers that would allow their use in emergency situations (Sánchez-Vizcaíno, JM, et al. Virus Res 2019, 256: 150-155). The protein subunit and DNA vaccines against the ASF virus that have been developed so far have not been successful to date (Turlewicz-Podbielska H, et al.; Viruses. 2021; 13(7):1212; Urbano, AC, and Ferreira, F. Emerg. Microbes Infect. 2022, 11 (1), 2021-2033).Therefore, obtaining an effective vaccine against the disease caused by ASFV remains a necessity for the development of the global swine industry. Explanation of the invention.
[0009] The present invention solves the problem of the lack of effective vaccines or treatments against the virus that causes ASF by providing a protein subunit vaccine composition that confers complete and early protection to pigs against infection by different genotypes of ASFV. This vaccine composition refers to an artificial chimeric protein consisting of a fragment of the viral protein p72 (p72t) fused to the extracellular segment of CD154 of pigs that could appear alone, fused to fragments of the chaperone protein B602L or in combination with the viral protein p30 or to a chimera between p30 and the extracellular fragment of CD 154 of pigs formulated in oily Montanide.
[0010] Said fragment of the p72 protein used as an antigen corresponds to an immunogenic region of the protein that is conserved among the different viral genotypes, comprised between amino acids 1 to 324 (SEQ ID NO. 1) and that contains 9 B epitopes and 8 T epitopes identified by a bioinformatic analysis of the sequence or comprised between amino acids 1 to 430 (SEQ ID NO. 7) that contains, in addition to the identified B and T epitopes, "gypsy arm" type beta barrel conformational epitopes. These fragments of p72 protect pigs against ASFV infection when fused to the extracellular segment of CD154 of pigs (SEQ ID NO. 2) using a flexible spacer segment rich in glycines, according to the results of a study that is disclosed in this invention, for the first time.
[0011] In a material embodiment of the invention, the synthetic DNA fragments encoding amino acids 1 to 324 and 1 to 430 containing the possible B and T cell epitopes, as well as the conserved conformational ones of p72 fused to the coding sequence of the extracellular segment of CD154 were expressed under the CMV promoter in CHOK1 cells growing in suspension.
[0012] In this material embodiment of the invention, synthetic DNA fragments encoding chimeric proteins containing the 430 amino acid fragment of p72 fused to a fragment of the B602L protein of ASFV comprised between amino acids 384 to 538 (SEQ ID NO. 9) or 398 to 465 (SEQ ID NO. 10), in turn fused to the extracellular segment of CD154 of pigs, were also expressed under the CMV promoter in CHOK1 cells growing in suspension. These fragments of the pB602L protein appear fused to the p72 protein in this form for the first time in the present invention. These designed chimeric proteins fold even more efficiently than the N-terminal domain of p72, increasing their stability, as a result of presenting less aggregation and less degradation.The addition of these fragments of the chaperone protein pB602L to the chimeric proteins introduces new B and T epitopes, which increases the immunogenicity properties and quality of the immune response generated.
[0013] All chimeric proteins p72tCD154 (SEQ ID NO. 3), p7243oCD154 (SEQ ID NO. 8), p7243oB6O2L LCD154 (SEQ ID NO. 11) and p7243oB6O2LcCD154 (SEQ ID NO. 12) were obtained in the culture supernatant forming high molecular weight structures with p72 epitopes recognized by sera from ASF-positive pigs and with a biological activity of stimulating the cellular immune response subsequently confirmed for the extracellular domain of porcine CD154. The design of these chimeras and the selected expression system guarantee the adequate structure for the formation of functional trimers for both p72t and CD154 that proved to be essential for the protective results against ASFV shown by these antigens compared to the non-protective results when p72 alone was used as the vaccine antigen (SEQ ID NO. 4). Unlike the native p72 protein, the designed segments do not include the C-terminal domain, which contains the most variable regions responsible for the different viral serotypes.In this way, the chimeric proteins of the present invention generate a neutralizing cross-reactive response against all epidemiologically relevant serotypes. The design of these chimeric proteins is unique and novel, since they have improved properties compared to the native protein, based on the greater immunogenicity of the conserved regions of p72 and therefore higher quality of the immune response generated in the vaccinated animal against different viral serotypes, and improved folding and stability. The p72 fragment comprising amino acids 1 to 430 contains, in addition to the B and T epitopes present in the smaller segment of amino acids 1 to 324, the complete "gypsy arm" type beta barrel domain, such that this fragment also forms topographical epitopes, which demonstrated advantages from the point of view of its production, purification and stability.Furthermore, a synthetic DNA fragment encoding the ASFV p30 protein (SEQ ID NO. 5) fused to a Histidine tag was expressed under the T7 promoter in the Escherichia coli strain BL21 D3 and fused to the extracellular domain of CD154 was expressed as chimeric protein p30CD154 (SEQ ID NO. 6) under the CMV promoter in CHOK1 cells. Both proteins purified from these sources were recognized by sera from ASF-positive pigs.
[0014] Immunization of pigs with two doses of the formulation containing the chimeric proteins p72tCD154, p7243oCD154, p7243oB6O2Li_CD154 or p7243oB6O2LcCD154 and also the formulations containing p72tCD154 combined with the p30 protein of the same virus or the p30CD154 chimera demonstrated the induction of high antibody titers against p72 and / or p30 depending on the antigens used, which were neutralizing of ASFV. The generation of a potent cellular response characterized by the significant induction of IFN gamma production 5 days after the first immunization and the significant increase in CD8+ lymphocytes essential for protection against ASFV in the groups immunized with the chimeras and their combinations with respect to the groups immunized with the p72 protein alone was also demonstrated. The challenge of pigs immunized with 10 4HADso (median hemadsorption units) of ASFV-G (Genotype II) or Lisbon / 57 (Genotype I) by intranasal route, demonstrated complete early protection in those groups immunized with the chimeras p72tCD154, p7243oCD154, P7243OB6O2LLCD154 or p7243oB6O2LcCD154 and the combinations of p72tCD154 with the p30 protein and the p30CD154 chimera only 5 days after the first immunization even when there was no significant antibody response against the viral infection. This protection was evidenced by the absence of clinical symptoms of the disease and by the absence of detection of viral DNA in tissue samples from vaccinated pigs. This sterilizing immunity was directly related to the presence of the p72tCD154, p7243oCD154, p7243oB6O2Li_CD154 or p7243oB6O2LcCD154 chimeras in the vaccine formulation and was significantly enhanced when the p30CD154 chimera was included in the vaccine formulation.These vaccine formulations containing one of the chimeras p72tCD154, p7243oCD154, p7243oB6O2Li_CD154 or p7243oB6O2LcCD154 were also able to generate a protective immune response in pregnant sows challenged with 10. 4 HADs of VPPA-G administered intranasally prevented the development of clinical signs of the disease and prevented virus replication in both mothers and fetuses, inhibiting vertical transmission of the virus.
[0015] In a material embodiment of the invention, immunization of pigs with the combination of the p72tCD154 and p30CD154 chimeras obtained in mammalian cells enhances the complete and sterilizing protection in pigs against ASFV, demonstrated by the presence of a significantly higher cellular response in the stimulation of CD8+ lymphocytes that positively correlates with the dose of CD154.
[0016] The present invention also discloses the use of a chimeric antigen comprising a conserved sequence fragment between amino acids 1 to 324 of the viral protein p72 (SEQ ID NO:1) or a fragment between amino acids 1 to 430 of the viral protein p72 (SEQ ID NO:7) or this 430 amino acid segment fused to a fragment of the B602L protein of ASFV comprised between amino acids 384 to 538 (SEQ ID NO. 9) or 398 to 465 (SEQ ID NO.10) all fused to the extracellular segment of CD154 of pigs (SEQ ID NO:2) for the manufacture of a medicament for the protection of pigs against infection with different genotypes of the African Swine Fever Virus (ASFV), as well as the use when this p72tCD154 antigen (SEQ ID NO:3) is combined with the p30 protein of the ASFV (SEQ ID NO:5) or a chimera consisting of the p30 fused to the extracellular segment of CD154 of pigs (SEQ ID NO:6) for the manufacture of a medicament to stimulate the humoral and cellular response against the ASFV and enhance the protective effect against the virus.
[0017] In another embodiment of the invention, a method is disclosed for stimulating the humoral and cellular response against ASFV and enhancing the protective effect against it, where the chimeric antigen consisting of SEQ ID NO:1 or SEQ ID NO:7 is fused to the extracellular segment of CD154 of pigs consisting of SEQ ID NO:2. Also disclosed is a method where the p72tCD154 antigen is combined with P30CD154.
[0018] Brief description of the figures
[0019] Figure 1. (A) Prediction of B epitopes in the ASFV p72 protein using the Bepipred Linear Epitope Prediction 2.0 program. (B) Evaluation of p72 amino acid hydrophilicity by the Parker method. (C) Evaluation of p72 amino acid flexibility by the Karplus-Schultz method. (D) Prediction of p72 amino acid surface accessibility by the Emini method. (E) Prediction of p72 amino acid residues forming beta turns by the Chou-Fasman method.
[0020] Figure 2. Alignment of the sequence defined as SEQ ID NO. 1 of the p72 protein fragment (p72t) with sequences reported for other ASFV genotypes. Conserved sequences appear as dots, and only amino acid changes are highlighted. Potential B epitopes are underlined, and T epitopes are underlined above the corresponding sequence.
[0021] Figure 3. Three-dimensional structure of the chimeric protein p72tCD154 from different angles obtained using the PyMol program.
[0022] Figure 4. Alignment of the sequence defined as SEQ ID NO. 4 of the p30 protein identical to that of the Georgia2007 strain with those of different ASFV strains described up to 2018.
[0023] Figure 5. Analysis of p30 protein variants corresponding to the Georgia2007, China / 2018 / AnhuiXCGQ and China / DB / HLJ / 2018 strains with respect to the ASF virus variants circulating in the period 2019-2022.
[0024] Figure 6. Topological diagram of the folding of the N-terminal domain of the ASF virus p72 glycoprotein. The gypsy arm-like beta-barrel domain is formed by two beta sheets (shaded regions): BIDG and CHEF.
[0025] Figure 7 Description of the 3D structure of the ASF virus p72 protein segment 1-430. (A) Ribbon diagram of the 3D structural model of the ASF virus p72 segment 1-430, colored in shades of gray, darkening toward the C-terminus. The location of the beta strands (Bl) of the gypsy arm beta barrel domain is shown. (B) The p72 fragment truncated from amino acids 1 to 324 (p72t) is shown.
[0026] Figure 8. 3D structure model of the chimeric protein fragments fused to CD154, consisting of the N-terminal domain 1-430 of the p72 glycoprotein fused at the C-terminal end to different fragments of the viral chaperone protein B602L. The N-terminal domain of p72 is shown in light grey, the B602L fragments in dark grey (A and B correspond to fragments 384 to 538 and 398 to 465, respectively), and the spacer segment in intermediate grey.
[0027] Figure 9. Expression of heterologous proteins in the culture supernatant of CHOK1 cells growing in suspension. (A) Western blot from a 12% SDS-PAGE gel transferred under reducing conditions and heated at 96°C for 10 minutes of the culture supernatant of CHOK1 cell clones expressing the chimeric proteins p72tCD154 and p30CD154 revealed with a peroxidase-conjugated anti-Histidine monoclonal antibody. (B) Analysis by 6% SDS-PAGE under non-reducing conditions of the p72 protein and the p72tCD154 chimera expressed by CHOK1 cell clones growing in suspension. (C) Western blot using a pool of sera from ASFV-infected pigs as the primary antibody and a peroxidase-conjugated anti-pig IgG as the secondary antibody.(D) Semiquantitative dot of 40 pL of culture supernatant of CHOK1 cell clones growing in suspension and expressing the chimeric proteins with the 430 amino acid fragment of p72 using a pool of sera from pigs infected with ASFV as primary antibody and a peroxidase-conjugated anti-pig IgG as secondary. A1-F1 40 pL of p72-His protein expressed in CHOK1 cells, purified at 98% by affinity to metal chelates applied at concentrations of 1.5 g / L, 1 g / L, 0.5 g / L, 0.25 g / L, 0.125 g / L and 0 g / L. G1 40 pL of supernatant of non-transformed CHOK1 cells. A2-D2 40 pL of supernatant of CHOK1 cell clones expressing p7243oCD154. A3-D3 40 pL of supernatant from CHOK1 cell clones expressing p7243oB6O2LcCD154. F2-3-G2-3 40 pL of supernatant from CHOK1 cell clones expressing p7243oB6O2Li_CD154.
[0028] Figure 10. 12.5% SDS-PAGE under reducing conditions of the disruption pellet of E. coli BL21 D3 transformed with the vector for expression of p30 protein (A), with the empty and native expression vector (B), at different induction times. Western blot from these SDS-PAGEs using a peroxidase-conjugated anti-Histidine monoclonal antibody (CD).
[0029] Figure 11. Total IgG titers specific to vaccine antigens measured by indirect ELISA. (A) Anti-p72 titers during the experiment in immunized pigs (B) Anti-p72 titers of all experimental groups on day 14 after the first immunization. (C) Anti-p30 titers during the experiment in immunized pigs. (D) Anti-p30 titers of all experimental groups on day 14 after the first immunization. Asterisks indicate statistically significant differences (* P < 0.05; ** P < 0.01; *** P < 0.001).
[0030] Figure 12. Neutralization of ASFV-G infection in Vero cells by serum from animals immunized with different ASF vaccine candidates measured by FACS using a monoclonal antibody (mAb) specific for p72. The percentage of p72 expression in Vero cells infected with ASFV-G preincubated with sera on day 28 is represented compared to the preimmune sera, considered as 100% expression. Asterisks indicate statistically significant differences (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).
[0031] Figure 13. IFN-gamma-producing cells specific for ASF virus antigens. (A) The mean and standard deviation per group are represented by the bars pointing in the positive direction. Asterisks represent statistically significant differences between times 5 and 35 within each group (t- test; * P < 0.05; *** P < 0.001). (B) and (C) IFN-gamma-producing cells are compared between experimental groups at 5 days after the first immunization and at 7 days after challenge, respectively. Asterisks represent statistically significant differences (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).
[0032] Figure 14. Confrontation of immunized pigs and controls with 10 4HAD50 of the ASFV-G strain by intranasal route, on day 28 after the first immunization. (A) Daily rectal temperature of pigs after viral challenge. The points represent the mean temperature per group, and the standard deviation is represented by bars in both directions. (B) Clinical score of pigs after viral challenge. (C) qPCR results of blood samples and oral swabs from pigs after viral challenge.
[0033] Figure 15. Confrontation of immunized pigs and controls with 10 4HAD50 of the Lisbon / 57 Wild boar strain 1957 Portugal by intranasal route, on day 28 after the first immunization. (A) Daily rectal temperature of pigs after viral challenge. The points represent the mean temperature per group and the standard deviation is represented by bars in both directions. (B) Clinical score of pigs after viral challenge. (C) qPCR results of blood samples and oral swabs from pigs after viral challenge.
[0034] Figure 16. Total IgG antibody response against p72 and p30 in pregnant sows immunized with different ASF virus antigen regimens and combinations. The values represented for each group correspond to the geometric mean. Asterisks indicate statistically significant differences (**** P<0.0001; ** P<0.01; * P<0.05).
[0035] Figure 17. Clinical signs of pregnant sows immunized with different antigens against the ASF virus after challenge with 10 4 HADso / mL of ASF-G intranasally. (A) Rectal temperature (B) Clinical score of challenged sows according to the clinical symptoms shown.
[0036] Figure 18. Total IgG titers specific to ASFV antigens measured by indirect ELISA in pigs immunized with a single dose of the vaccine formulations and challenged on day 5 post-immunization. The value represented for each group corresponds to the geometric mean. Asterisks indicate statistically significant differences (* P < 0.05; ** P < 0.01; **** P < 0.0001).
[0037] Figure 19. Induction of IFN-gamma-producing cells specific for ASF virus antigens after in vitro stimulation with the ASFV-G viral strain of PBMCs from immunized and control animals 5 days after the first immunization. Data represent the mean per group. Asterisks represent statistically significant differences with respect to the control group (** P < 0.01; **** P < 0.0001).
[0038] Figure 20. Rectal temperature and clinical signs of pigs immunized with a single dose of different antigens against ASF virus after challenge with 10 4 HADso / mL of ASFV-G (A) or Lisbon / 57 (B) intranasally.
[0039] Figure 21. Relative cytokine expression by CD8+ and CD4+ T cells isolated from tonsils of pigs vaccinated against ASFV using actin as the reference gene. Data represent the mean per group. Standard deviation is represented by the bars pointing in the positive direction. Asterisks represent statistically significant differences (* P < 0.05; **** P < 0.0001).
[0040] The present invention demonstrates the horizontal and vertical protective capacity of a vaccine formulation against ASFV infection in pigs, which contains a fragment of the p72 protein comprising amino acids 1 to 324 or 1 to 430 fused to the extracellular domain of CD154 of pigs expressed in CHOK1 cells growing in suspension. This fragment from amino acids 1 to 430 of the ASFV p72 protein may or may not be fused to the fragments of the B602L protein of the same virus comprised between amino acids 384 to 538 or 398 to 465, respectively, to form fusion proteins with the extracellular domain of CD154 of pigs. The design of these chimeras is unique and novel since they have improved properties compared to the native protein, based on the greater immunogenicity of the conserved regions of p72.Unlike the native p72 protein, the designed segments, by not including the C-terminal domain, which contains the most variable regions responsible for the different viral serotypes, generate a greater cross-reactive neutralizing response against all epidemiologically relevant serotypes. The p72 fragment comprising amino acids 1 to 430 contains, in addition to the B and T epitopes present in the smaller segment of amino acids 1 to 324, the complete "gypsy arm" type beta barrel domain, such that this fragment also forms topographic epitopes, which demonstrated advantages from the point of view of production, purification and stability of the chimeric protein due to its greater folding and the decrease in aggregation and degradation phenomena.All these features optimize the antigen production process in the heterologous system and guarantee greater economic feasibility, in addition to the generation of specific humoral and cellular responses in pigs immunized with the oily formulation containing them, which efficiently protects them against ASFV infection. The addition of fragments of the chaperone protein pB602L to the chimeric proteins improves the folding of the 430-amino acid fragment of p72 and also introduces new B and T epitopes to the immunogens, which increase the immunogenicity properties and quality of the immune response generated. The protection of all the designed chimeric proteins against ASFV infection is evident five days after a single immunization when there is no evident humoral response.This protection includes inhibition of viral replication in immunized pigs and inhibition of transmission of ASFV from immunized mothers to fetuses.
[0041] When the chimeric antigen p72tCD154 is combined with p30, its protective capacity is enhanced and when it is combined with the chimera p30CD154, a significantly higher CD8+ lymphocyte cellular response is obtained, allowing protection to be obtained with a reduction in antigen doses.
[0042] The present invention describes for the first time protective vaccine compositions against ASFV infection in pigs with an inhibition of horizontal and vertical transmission of the virus and therefore offers a practical solution for the prevention of ASF that does not exist to date.
[0043] Detailed description of implementation methods / Examples of implementation
[0044] Example 1. Bioinformatic analysis of the sequences of the p72 and p30 proteins of ASFV.
[0045] The sequences of the p72 and p30 proteins from different ASFV strains were obtained from the NCBI (National Center for Biotechnology Information) database. Multiple sequence alignment was performed using the Clustal Omega bioinformatics tool. The prediction of B epitopes was carried out using the bioinformatics tool Antibody Epitope Prediction 2 available on the IEDB Analysis Resource (Immune Epitope Database) site. In addition, the probabilities of hydrophilicity, The flexibility, surface accessibility and probability of forming part of beta turns of each of the amino acids of the p72 protein were evaluated using the Parker, Karplus-Schultz, Emini and Chou-Fasman methods, respectively. T cell epitope prediction was performed using the NetCTL 1.2 bioinformatics tool using 0.97 and 0.80 as threshold parameters. specificity and sensitivity, respectively. Finally, the three-dimensional structure of the designed chimeric protein was predicted using the Rosetta bioinformatics tool, which includes algorithms for the Computational modeling and protein structure analysis. Among the prediction services provided by Rossetta, the Robetta server was used, which predicts the three-dimensional structure of the protein. For the visualization of the predicted three-dimensional structure, the Pymol program (version 1.8.6, 2015) was used.
[0046] Analysis of the amino acid sequence of the p72 protein using the bioinformatics tool for B cell epitope prediction showed a greater presence of these towards the amino terminal region of the protein, with the highest score values awarded by the analysis with respect to the cutoff value appearing in this region of the protein (Figure 1 A). From the analysis of the amino acid residues of p72, it was predicted that around 50% were hydrophilic and flexible, with a predominance of these towards the N terminus of the protein. These hydrophilic and flexible residues should be part of short sequences of beta turns with a conformation that imposes a sharp 180-degree turn to the polypeptide chain that generally connects the alpha or beta structures (Figure 1 B and C). Approximately 35% of the aa residueswere accessible on the surface of the protein with a greater number at the amino-terminal end, although the highest scores were towards the carboxyl-terminal half (Figure 1 DE). All these analyses support the prediction of the B epitopes obtained for the p72 protein and sustain its high immunogenic capacity to trigger an effective B lymphocyte response. Based on the analyses performed, it was decided to use as a vaccine antigen a fragment of the protein comprised between aa 1 to 324 of the protein (SEQ. ID NO. 1) that also showed the highest sequence identity between the different reported viral genotypes varying between 97 and 100%. The sequence of the fragment used was 100% identical to the genotype II viral strains that have been responsible for the outbreaks of the disease outside of Africa in the last 10 years and 99.54% to the sequence of genotype I viral strains that were responsible for the first appearance of this disease outside Africa in the last century (Figure 2). The most different sequences, with 97–98% sequence identity, were those of genotypes VIII, IX, and X, circulating only in Africa.
[0047] Table 1 shows the score values above the threshold value of 0.75 assigned to different peptides of the p72 fragment comprised between amino acids 1 to 324 by the NetCTL 1.2 bioinformatics tool as possible cytotoxic T lymphocyte epitopes.
[0048] Table 1. Score values above the threshold value of 0.75 assigned to different peptides of the p72 fragment
[0049] NO, PEPTIDES POSITION ASSIGNED VALUE
[0050] The modeling of the three-dimensional structure of this fragment of p72 (SEQ. ID NO.1) fused to the extracellular segment of CD154 of pigs (SEQ. ID NO.2) to generate the chimeric p72tCD154 (SEQ. ID NO.3) is shown in Figure 3.
[0051] Multiple sequence alignment of the p30 protein showed high similarity among the 12 ASF virus strains studied, which could also translate into structural and functional conservation of the protein. Furthermore, in cases where amino acid substitutions exist in the sequence, a predominance of semi-conservative substitutions is observed, implying that there should be no significant variation in the protein's immunogenic characteristics (Figure 4). The p30 sequence used as antigen (SEQ. ID NO. 4) was 100% identical to the p30 protein sequences of the ASFV strains Georgia2007, China / 2018 / AnhuiXCGQ and China / DB / HLJ / 2018 that belong to genotype II and have been responsible for the ASF outbreaks in Eastern Europe and later in Asia and between 96% and 99% identical to the strains that have recently circulated in Korea, Japan, Mongolia, India, China and Vietnam (Figure 5).
[0052] Example 2. Design of chimeric artificial proteins comprising the complete N-terminal domain of the p72 glycoprotein of the African Swine Fever virus.
[0053] Other chimeric proteins of the present invention are based on the complete N-terminal domain of the p72 protein, comprised between amino acids 1 to 430, excluding the C-terminal domain where the most variable regions responsible for the described serotypes are located. The introduction of these alternative designs allows maintaining the favorable immunological properties of the 1-324 fragment, but adds some desirable properties to the chimeric proteins, not only from an immunological point of view but also at the level of their physicochemical and biophysical properties that favor better folding, and ease of obtaining them with an increase in their stability and quality and consequently in the immune response.
[0054] As seen in Figure 6, the fold of this domain is of the gypsy arm beta barrel type, formed by two antiparallel beta sheets. The domain includes three large insertions contained in the fragments from amino acids 110 to 188, 204 to 327 and 361 to 407. These insertions in turn contain beta strands that interact with each other and form topographical epitopes. The folding of the insertion regions depends on the correct folding of the beta barrel since this forms the structural framework of the entire protein. The surface of the gypsy arm beta domain also exposes potential topographical epitopes. Since the p72 fragment comprised from amino acids 1 to 324 excludes the G, H and I strands of the beta barrel domain, the conformational epitopes resulting from the folding of these insertions are not obtained, and there is less structural stability of the protein (Figure 7).
[0055] The entire N-terminal domain of p72 was also fused to fragments of the chaperone protein pB602L (Figure 8). The structural basis for understanding how the chaperone pB602L exerts its function in p72 folding is currently unknown, and the binding regions between the two proteins have not been determined. For the design of the chimeric proteins, the structure of the complex was predicted using bioinformatics methods. The result indicated that the fragment comprised from amino acids 398 to 465 of the B602L protein potentially participates in the binding by interacting with the BIDG beta sheet of the beta-barrel domain, which is consistent with its favorable role in domain folding. Therefore, both fragments of the p72 and B602L proteins were fused using a flexible glycine-rich spacer segment with feasible stereochemistry.Another similar variant was designed, using a larger pB602L fragment containing the former.
[0056] Example 3. Synthesis, cloning and expression of the nucleotide sequences encoding the p30 and p72 proteins and the chimeric proteins p72tCD154, p72 43 oCD154, p7243oB6O2l_ L CD154, p72 43 oB6O2LcCD154 and p30CD154.
[0057] The 990 bp and 1290 bp DNA sequences encoding amino acids 1 to 324 and amino acids 1 to 430, respectively, containing the conserved B and T epitopes of ASFV p72 fused to the coding sequence of the extracellular segment of CD154 of pigs with an intervening spacer sequence and the 1978 bp sequence coding for the complete p72 were obtained by chemical synthesis, as well as the coding sequences for the fragments of the B602L chaperone protein that were then fused to the 430 amino acid fragment of p72. These duly assembled sequences were cloned under the CMV promoter in a lentiviral vector obtained in our laboratory from modifications of a commercial vector.This vector along with other helper plasmids was used to transfect 293FT cells where high titers of recombinant lentivirus were generated that were then used to transduce CHOK1 cells with MOI of 100 and 500 with 4 replicates per condition including a non-transduced control sample. After an overnight incubation at 37°C and 8% CO2 atmosphere, the cells were incubated for approximately fifteen days in Blasticidin selection medium until 100% of the cells died in the control plates and the growth of colonies of cells resistant to the antibiotic in the transduced plates. Cell pulses generated at both MOIs were cloned by limiting dilution and around 30 clones were obtained from each condition and expanded to test the expression levels of the chimeras p72tCD154 (SEQ. ID NO.3), p7243oCD154 (SEQ. ID NO.8), P7243OB6O2LLCD154 (SEQ. ID NO.11), p7243oB6O2LcCD154 (SEQ. ID NO.12) and the p72 protein (SEQ.ID NO.4) respectively and select the best clones in terms of their growth rate and their level of expression of heterologous proteins.
[0058] On the other hand, the coding sequence of the ASFV p30 protein (SEQ. ID NO. 5) was cloned fused to a 6 His tag under the T7 promoter and expressed in the E. coli strain BL21 D3. In addition, this sequence was cloned under the CMV promoter fused to the coding sequence of the extracellular segment of CD154 from pigs with an intervening spacer sequence and expressed in CHOK1 cells growing in suspension. The procedure to obtain the p30CD154 chimera (SEQ. ID NO. 6) in the CHOK1 cell supernatant was the same as that described above for the p72 variants.
[0059] Figure 9A shows the monomers of the p72tCD154 and p30CD154 chimeras expressed in the supernatant of the selected clones under reducing conditions and heated for 10 minutes at 96°C. The p72tCD154 chimera and p72 expressed by CHOK1 cells were recognized by a pool of sera from pigs infected with ASFV (Figure 9 B and C), as well as the p7243oCD154, p7243oB6O2LcCD154 and P7243OB6O2LLCD154 chimeras (Figure 9D).
[0060] To stop the expression of p30His in E. coli, plasmids containing the p30 coding sequence under the T7 promoter were used to transform BL21 D3 chemo-competent cells by treatment with CaCL using a heat shock protocol. From the selection antibiotic-resistant colonies transformed with the empty vector or with p30 and the untransformed control strain, 300 mL bulk cultures were inoculated and grown at 37 °C with shaking on a shaker at 250 rpm until an OD at 600 nm between 0.5 and 0.8 was reached, at which time IPTG was added at a final concentration of 1 mM to induce protein expression for 8 hours. Samples were taken from the cultures at the time of induction and then every 2 hours. Expression of p30 protein was visible from 2 hours after induction until the end of the culture (Figure 10).
[0061] The supernatants of CHOK1 cells expressing the proteins p72, p72tCD154, p7243oCD154, p7243oB6O2LcCD154, p7243oB6O2Li_CD154 and p30CD154 were clarified by centrifugation and filtration. The p72 His filtrate was applied to a N¡-NTA affinity column according to the manufacturer's recommendations, with a gradient of different imidazole concentrations for washings and elution. In the case of chimeric proteins, the filtrate was purified by molecular exclusion. In the case of the p30 protein expressed in E. coli, once the biomass was obtained, the cells were mechanically disrupted using a Gaulin press. The solubilization of the inclusion bodies was carried out using 8M urea as a chaotropic agent. Protein purification was performed by metal chelate affinity chromatography with a gradient of different imidazole concentrations.The fractions collected during the purification process were analyzed by SDS-PAGE under reducing conditions and Western blot assays revealed with an anti-Histidine antibody.
[0062] Example 4. Evaluation of the efficacy of vaccine candidates against African Swine Fever virus in pigs.
[0063] In order to evaluate the humoral and cellular responses and the efficacy of the immune response generated by vaccine candidates against African swine fever (ASF) virus, nine-week-old Duroc / Yorkshire crossbred pigs weighing 25-30 kg, negative for CSF and ASF, were immunized intramuscularly with different combinations of antigens in an oily formulation containing Montanide in a 60 / 40 (v / v; aqueous / oily) ratio with two doses and an interval of 21 days between them. The animals were fed 2 kg / per animal / per day of commercial feed and water ad libitum. All experimental procedures were performed according to the guidelines and procedures for the use of laboratory animals. The experimental groups were as follows:
[0064] Group (8 animals): Non-immunized controls
[0065] Group 2 (8 animals): Immunized with two doses of 50 .g / 1 mL of the p72t-CD154 protein.
[0066] Group 3 (8 animals): Immunized with two doses of 50 .g / 1 mL of the p72 protein.
[0067] Group 4 (8 animals): Immunized with two doses of 25 .g / 1 mL of each of the p72t-CD154 and p30 proteins respectively adjuvanted in the same preparation.
[0068] Group 5 (8 animals): Immunized with two doses of 15 µg / 1 mL of each of the p72t-CD154 and p30-CD154 proteins, respectively, adjuvanted in the same preparation. Group 6 (8 animals): Immunized with two doses of 50 µg / 1 mL of the p7243oCD154 protein.
[0069] Group 7 (8 animals): Immunized with two doses of 50 pg / 1 mL of the P7243OB6O2LLCD154 protein.
[0070] Group 8 (8 animals): Immunized with two doses of 50 pg / 1 mL of the p7243oB6O2LcCD154 protein.
[0071] Serum was collected from the animals every 7 days to determine antibody titers. The challenge was performed on day 28. The total IgG titer specific to the viral antigens p72 and p30 was determined using an indirect ELISA developed in our laboratory.
[0072] For this purpose, High binding plates (Costar, USA) were coated with 100 μL of p72 or p30 at a concentration of 10 μg / mL overnight at 4°C. Four washes were then performed with 1X PBS-0.05% Tween. These plates were blocked with 3% skim milk in 1X PBS for 1 h at 37°C and then 100 μL of serial dilutions in PBS based on a 1:2 ratio of the study sera inactivated at 56°C were applied for 30 minutes starting with a dilution of 1:500 up to 1:64,000. The plates were incubated at 37°C for 1 h and then four washes were performed with 1X PBS-0.05% Tween. Subsequently, 100 pL of a 1:10,000 dilution of a peroxidase-conjugated pig anti-IgG (Sigma, USA) was added. The plates were incubated again at 37°C for 1 h. After 4 washes under the same conditions as above, the reactions were revealed using a substrate solution containing 0.1% tetramethylbenzidine (TMB, 1 mg / mL in DMSO) in 0.1 M citric acid and 0.2 M Na2HpO4, pH 5, and 0.006% hydrogen peroxide, for 10 min at room temperature. After stopping the reaction with 50 pL of 2 M H2SO4, the absorbances of the wells were measured at a wavelength of 450 nm in an ELISA plate reader. The sample titer was defined as the serum dilution where the absorbance was greater than or equal to twice the absorbance of the pre-immune serum. Antibody titers were compared by ANOVA followed by a Bonferroni multiple test performed using the Prism statistical program (version 9.0 for Windows; GraphPad Software, USA).
[0073] All immunized animals developed total IgG titers specific for p72 starting on day 14 after the first immunization (Figure 11 A). However, the titers of the groups immunized with the chimeras combined or not with p30 on day 14 were significantly higher compared to those of the group immunized with p72 alone (Figure 11 B). Furthermore, seroconversion on day 14 of the groups immunized with the chimeras was 100% of the animals compared to a seroconversion of 60% in the group immunized with p72 alone. Animals in groups 4 and 5 also developed total IgG titers specific for p30 starting on day 14 after the first immunization (Figure 11 C), with those of group 5 being significantly higher on that day (Figure 11 D).
[0074] The neutralizing capacity of these antibodies against the ASF virus was assayed by FACS (Fluorescence Activating Cell Sorting). To do this, Vero cell monolayers cultured in DMEM (Dulbecco's modified Eagle's medium) medium with 5% (v / v) fetal bovine serum and gentamicin at 100 μg / mL were infected at an MOI of 1 using a viral strain multiplied in these cells with a passage number < 15 derived from the highly virulent parental virus of the Georgia / 2007 isolate (ASFV-G). This viral strain was previously incubated for 18 h at 37 °C with a 1 / 5 dilution of pre-immune or immune sera on the day of challenge, respectively.The percentage of cells expressing the major viral capsid protein p72 was determined 16 hours post-infection using a monoclonal antibody against this protein conjugated to FITC at a 1:10 dilution by flow cytometry on a CyFlow Space Cytometer (Partee) equipped with FloMax® software. Each sample was assayed in duplicate. Vero cells without the addition of the conjugated mAb were used as unlabeled controls to determine the baseline autoflorescence signal of the samples. Analysis of the acquired data was performed using FlowJo v.10 software (FlowJo LLC, Tree Star). The expression of p72 of Vero cells infected with ASFV-G preincubated with preimmune sera was considered as 100% from which the % expression of p72 of Vero cells infected with ASFV-G preincubated with immune sera was calculated on day 28 when the challenge was performed.Statistical analysis of the percentages was performed by ANOVA followed by a Bonferroni multiple test using the Prism statistical program (version 9.0 for Windows; GraphPad Software, USA). As seen in Figure 12, the highest percentages of inhibition of p72 expression by Vero cells infected with ASF virus were obtained when sera from pigs immunized with the combination of the chimeric proteins p72t-CD154 and p30-CD154 were used, and whenever the chimeric proteins with p72 fragments fused to CD154 were used as vaccine antigens, there were significantly higher percentages of inhibition compared to when p72 alone was used as the antigen.
[0075] For cellular response studies, peripheral blood mononuclear cells (PBMCs) were isolated from three animals from each group by Ficoll centrifugation (GE Healthcare Life Sciences) five days after the initial immunization and seven days after challenge and resuspended in RPMI 1640 medium supplemented with 1X antibiotic / antimycotic solution and 10% fetal bovine serum. Antigen-specific IFN-γ response was determined by a BASIC porcine IFN-γ ELISpot assay (MABTECH). The assay was performed using 96-well plates according to the manufacturer's instructions. Briefly, plates were coated overnight at 4°C with 100 pL of the anti-IFN-γ capture antibody prepared at 10 pg / mL. The plates were then washed five times with 200 pL of sterile PBS and blocked with culture medium for 2 h at 37 °C. 5 x 10 was then added to each well. 5PBMC from each triplicate sample were premixed with 0.05 MOI of ASFV-G. As controls, cells were added in the absence of virus (negative control), or cells mixed with the mitogen concanavalin A (Con A) at 6 pg / mL as a positive control. After 36 h of incubation at 37 °C, the plates were washed 5 times with 200 pL per well of PBS and then the biotinylated anti-IFN-γ detection antibody (P2C11) was added at 0.5 pg / mL in PBS + 0.5% FBS for 2 h at room temperature. Subsequently, the plates were washed and streptavidin-ALP diluted 1:1000 in PBS with 0.5% FBS was added. After a 1-h incubation at room temperature, the plates were washed again with PBS and developed with 100 µL of the substrate (cat. # 3650-10) per well for 30 minutes. The reaction was stopped by washing the plate with hard water. The plates were allowed to dry overnight, and the spots were counted.Antigen-specific IFN-gamma-producing cells were calculated by subtracting the number of spots obtained in PBMC samples stimulated with ASF-G from the number of spots obtained for the same sample in the absence of virus. Group means were compared by ANOVA followed by Turkey's multiple comparisons test performed using Prism statistical software (version 9.0 for Windows; GraphPad Software, USA).
[0076] The results showed that even in the absence of specific IgG titers against p72 and p30 in pigs immunized by intramuscular injection with the chimeras in any of their combinations, 5 days after the first immunization there was significant stimulation of IFN gamma production compared to the response of control pigs and to those immunized with p72 protein alone, which behaved the same as the non-immunized group (Figure 13). In the case of the group immunized with the combination of p72t-CD154 and p30-CD154 chimeras, the stimulation of IFN gamma production was significantly higher than in the groups immunized with the chimeras containing p72 fragments fused to CD154 alone, demonstrating the enhancing effect of CD154 doses on this response (Figure 13B).Seven days after the challenge, there was significant stimulation of IFN gamma production compared to the control group in all groups immunized with the p72 chimeras and there were no differences between the control group and the group immunized with p72 alone.
[0077] The challenge of all experimental groups was carried out under biosafety level 3 containment conditions following the protocols approved by the Institutional Animal Care and Use Committee. The pigs were inoculated on day 28, 7 days after the last immunization, by instilling 1 mL containing 10 4HADso (median hemadsorption units) of ASFV-G or Lisbon / 57 Wild boar 1957 Portugal were administered intranasally to four animals per group, at independent sites. Rectal temperature was recorded daily for 16 days post-challenge, and clinical signs of anorexia, depression, purple skin discoloration, wobbly gait, diarrhea, and cough were summarized in a clinical score. Fever was considered when the rectal temperature was above 40°C for two or more consecutive days. Samples (blood and oral swabs) were collected on days 2, 4, 8, and 16 post-inoculation for detection of the presence of virus by qPCR and virus titration in Vero cell cultures by FACS as described previously.
[0078] From the fourth day post-challenge, all animals in the control group developed clinical signs compatible with ASF, such as fever with temperatures above 41°C, anorexia, and ataxia, regardless of the ASFV genotype with which they were infected (Figures 14 and 15). From the sixth day of viral challenge with both viral genotypes, a clear deterioration in the health of these animals was observed, including diarrhea, conjunctivitis, respiratory disorders, severe prostration, and nervous symptoms, so the animals in this group were sacrificed for ethical reasons. Necropsies revealed lesions specific to ASF infection. All animals immunized with the p72 chimeras combined or not with p30 were able to overcome the challenge without clinical manifestations of the disease (Figures 14B and 15B), regardless of the ASFV genotype with which they were infected.No macroscopic pathological lesions compatible with ASF were observed at 16 dpc when all animals were sacrificed. In animals vaccinated intramuscularly with p72 alone, severe clinical signs compatible with ASF were observed in one animal infected with the Lisbon / 57 strain and in two with the ASFV-G strain, which had to be sacrificed around the eighth day post-challenge. The remaining pigs in the group showed mild symptoms such as anorexia and depression, but recovered between 8 and 10 days post-challenge, regardless of the ASFV genotype with which they were infected.
[0079] The presence of virus in blood and oral swabs after challenge was demonstrated in animals in the control group and in those in group 3 immunized with p72 alone. Blood samples and oral swabs from the remaining groups were negative for ASF by both PCR and FACS at all times studied (Figures 14C and 15C). Data from groups not shown in the figure are due to the fact that the animals in that group clearly deteriorated in health and were sacrificed for ethical reasons.
[0080] Example 5. Study of the inhibition of vertical transmission of ASFV by African Swine Fever virus vaccine candidates Twenty-eight Duroc / Yorkshire crossbred sows serologically negative for CSF and ASF gestated by artificial insemination were distributed into seven experimental groups and immunized intramuscularly with different antigens adjuvanted in oily Montanide in a 60 / 40 (v / v; aqueous / oily) ratio.
[0081] Group (4 sows): Non-immunized controls
[0082] Group 2 (4 sows): Immunized with two doses of 50 pig / 1 ml of the p72t-CD154 protein with an interval of 21 days between them, starting the first vaccination on day 62 of gestation.
[0083] Group 3 (4 sows): Immunized with two doses of 50 .g / 1 mL of the p72 protein with an interval of 21 days between them, starting the first vaccination on day 62 of gestation.
[0084] Group 4 (4 sows): Immunized with a dose of 50 .g / 1 mL of each of the chimeric proteins p72t-CD154 and p30-CD154 adjuvanted in a single preparation on day 76 of gestation.
[0085] Group 5 (4 sows): Immunized with two doses of 50 .g / 1 mL of the chimeric protein p7243o-CD154 with an interval of 21 days between them, starting the first vaccination on day 62 of gestation.
[0086] Group 6 (4 sows): Immunized with two doses of 50 .g / 1 mL of the chimeric protein p7243oB6O2Li_CD154 with an interval of 21 days between them, starting the first vaccination on day 62 of gestation.
[0087] Group 7 (4 sows): Immunized with two doses of 50 .g / 1 mL of the chimeric protein p7243oB6O2LcCD154 with an interval of 21 days between them, starting the first vaccination on day 62 of gestation.
[0088] Serum was extracted from sows prior to primary vaccination and then every 7 days until the day of challenge to determine antibody titers as described in Example 4 as the reciprocal of the dilution at which the OD at 450 nm of the test sera in the ELISA was twice the OD of the pre-immune sera. Antibody titers were compared by ANOVA followed by Turkey’s multiple test performed using the Prism statistical program (version 9.0 for Windows; GraphPad Software, USA). All immunized sows developed total IgG titers specific against p72 from day 14 after the first immunization. These titers were statistically significantly higher on the day of challenge in groups 2, 4, 5, 6 and 7 compared to the group immunized with p72 alone, but with no differences between them.Sows in group 4 that received only one dose of vaccine and were challenged 14 days after that immunization had significantly higher antibody titers than pigs in all other groups on day 14. Pigs in that group also developed specific antibody titers against p30 of a magnitude similar to those generated against p72 (Figure 16).
[0089] At 90 days of gestation all sows were challenged with 10 4HADso / mL of ASFV-G intranasally. At that time of gestation, according to the immunization schedules applied to each experimental group, groups 2, 3, 5, 6, and 7, which received two doses of 50 μg of the antigens with an interval of 21 days between them, were challenged 7 days after the last immunization, and group 4, which received a single dose of 50 μg of each of the p72t-CD154 and p30-CD154 chimeras combined in a single preparation, was challenged 14 days after that single immunization. Clinical signs of the disease were recorded daily for 14 days, and blood samples and oral swabs were collected on days 2, 4, 8, 10, and 14 post-inoculation for detection of the presence of the virus by qPCR.
[0090] Unvaccinated sows developed clinical signs starting at 4 dpc, consisting of apathy and anorexia, progressing with an increase in rectal temperature between 39.5 and 41 °C, weight loss, and diarrhea (Figure 17). They subsequently showed prostration and were euthanized at 8 dpc. None of the immunized sows in groups 2, 4, 5, 6, and 7 showed clinical signs of the disease. However, in group 3, two sows showed clinical manifestations at 7 dpc, which subsequently disappeared in one of them; the other was euthanized at 10 dpc. The other two sows in that group showed some symptoms of the disease at 14 dpc when they were euthanized, with rectal temperatures above 39 °C and a deterioration in the clinical score (Figure 17). At 14 dpc, all other sows were euthanized.At the time of slaughter, five randomly selected fetuses from each sow were necropsied to assess macroscopic lesions consistent with ASF in various organs. The presence of ASFV was assessed by qPCR in fetal blood and tissue samples.
[0091] In line with these clinical results, all oral swab and blood samples from sows in groups 2, 4, 5, 6, and 7 were negative for ASFV at all time points. Some oral swab samples from group 3 on day 4 post-challenge and one blood sample were positive by ASFV-specific qPCR with a Ct between 30 and 35. By day 8, all swab samples from sows in group 3 immunized with p72 alone were positive, and two blood samples were positive as well. From day 10, all swab and blood samples from this group 3 remained positive until slaughter. In contrast, all blood samples and oral swabs from control sows were positive for ASFV with Ct values <30 from day 4 post-challenge (Table 2). Data from groups not shown in the table are due to animals in this group being slaughtered for ethical reasons.
[0092] Table 2. qPCR results of blood samples and oral swabs from pregnant sows in each experimental group after viral challenge with 10 4 HADso / mL of ASFV-G intranasally.
[0093]
[0094] Pathological analysis of fetuses from control sows showed hemorrhagic tonsils, a discolored spleen, and the presence of abdominal fluids. In all cases, qPCR results were positive in blood, tonsils, and spleen. Fetuses from group 3 sows immunized with p72 protein alone also had positive samples in blood and tissues studied. All samples from fetuses from immunized dams in groups 2 and 4 were negative (Table 3).
[0095] Table 3. qPCR results of blood, spleen and tonsil samples from the 5 fetuses from the gestated sows in each experimental group on the day of slaughter.
[0096] Example 6. Study of early protection of vaccine candidates against African Swine Fever virus in pigs
[0097] Nine-week-old Duroc / Yorkshire crossbred pigs weighing 25–30 kg, negative for CSF and ASF, fed 2 kg / animal / day of commercial feed and water ad libitum, were assigned to experimental groups that were immunized intramuscularly with antigen formulations containing oily Montanide in a 60 / 40 (v / v; aqueous / oily) ratio. All procedures were performed according to the guidelines for the use of laboratory animals. Group 1 (8 animals): Non-immunized controls.
[0098] Group 2 (8 animals): Immunized with a dose of 50 .g / 1 mL of the p72t-CD154 protein.
[0099] Group 3 (8 animals): Immunized with a dose of 50 .g / 1 mL of the p72 protein.
[0100] Group 4 (8 animals): Immunized intramuscularly with a dose of 25 μg Z1 each of the chimeric proteins p72t-CD154 and p30-CD154 adjuvanted in the same vaccine preparation. Group 5 (8 animals): Immunized with a dose of 50 μg / 1 ml of the chimeric protein p7243o-CD154.
[0101] Group 6 (8 animals): Immunized with a dose of 50 pig / 1 m L of the chimeric protein P7243OB6O2LLCD154.
[0102] Group 7 (8 animals): Immunized with a dose of 50 pig / 1 ml of the chimeric protein p7243oB6O2LcCD154.
[0103] Serum was extracted from the animals on days 0, 5, 12 and 19 to determine the total IgG antibody titers specific for the viral antigens p72 and p30 using indirect ELISAs developed in our laboratory and described in Example 4. Antibody titers are expressed as the reciprocal of the dilution at which the OD at 450 nm of the test sera in the ELISA was twice the OD of the pre-immune sera. The anti-p72 titers of the experimental groups at 5, 12 and 19 days after immunization were compared by ANOVA followed by Turkey's multiple test using the Prism statistical program (version 9.0 for Windows; GraphPad Software, USA). In the case of the anti-p30 titers, those of group 4 were compared with those of the control group by a t test at each time point using the Prism statistical program (version 9.0 for Windows; GraphPad Software, USA). On day 5 after immunization, the challenge was performed with 104 HADso of ASFV-G or Lisbon / 57 by intranasal route by dividing each group into two subgroups of 4 animals as also described in example 4 under biosafety level 3 containment conditions following the protocols approved by the Institutional Animal Care and Use Committee.
[0104] By day 5 post-immunization, none of the animal groups had significantly higher total IgG antibody titers against the vaccine antigens than the non-immunized controls. On day 12 post-immunization and day 7 post-challenge, antibody titers against p72 were statistically significantly higher in all pigs immunized with the p72 chimeras than in the controls and in the group immunized with p72 alone. Pigs in the control groups and immunized with p72 alone were euthanized for ethical reasons on day 8 post-challenge (day 13 post-immunization). On day 19 post-immunization and day 14 post-challenge, the titers of the groups immunized with the p72 chimeras did not show statistically significant differences from the titers of pigs immunized with the combination of p72t-CD154 and p30-CD154 chimeras (Figure 18).Animals in group 4 immunized with the combination of the p72t-CD154 and p30-CD154 chimeras also developed total IgG titers specific against p30 that were statistically significantly different from the controls from day 12 after immunization and seven days after the challenge (Figure 18).
[0105] On the day of challenge, 5 days after immunization, peripheral blood mononuclear cells (PBMC) were isolated from four of the animals in each group to study the cellular response following the same procedure described in example 4 for specific induction of IFN-gamma production by in vitro stimulation of these cells with the ASFV-G viral strain. The means of IFN-gamma expression by group were compared by ANOVA followed by Turkey's multiple comparisons test using the Prism statistical program, version 9.0 for Windows; GraphPad Software, USA. The results showed that in pigs immunized with the p72 chimeras or those immunized with the p72t-CD154 chimera combined with the p30-CD154 chimera, 5 days after the first immunization there was significant stimulation of IFN gamma production compared to the response of control pigs and those immunized with the p72 protein alone.In the case of group 4 immunized with the combination of chimeras, the production of IFN gamma was significantly higher than that of the groups immunized with the p72 chimeras alone, as expected according to the results shown in example 4 (Figure.
[0106] 19).
[0107] After the challenge, the (rectal) temperature of the pigs in the control group and those vaccinated with p72 increased from 4 dpc with values above 39°C (Figure
[0108] 20) and symptoms such as anorexia, a staggering gait, depression, purple skin discoloration, diarrhea, and coughing were evident, regardless of the viral genotype with which they were challenged. All pigs in these two experimental groups had to be euthanized on the eighth day after viral challenge. Pigs in groups 2, 4, 5, 6, and 7 remained clinically healthy throughout the experiment (Figure 20). All animals that did not become ill were euthanized 12 days after challenge. Blood samples and oral swabs collected on days 2, 4, 8 and 14 post-challenge from pigs in groups 2, 4, 5, 6 and 7 were always negative by specific qPCR for the two ASFV genotypes used in the viral challenge, while in animals in the control group and those immunized only with p72, the presence of virus in the blood and oral swabs was demonstrated from 2 and 4 dpc (Table 4).
[0109] Data for groups not shown in the table are due to animals in the group being sacrificed for ethical reasons.
[0110] Table 4. qPCR results of blood samples and oral swabs from pigs in each experimental group after viral challenge with 10 4 HADso / mL of ASFV-G or L57 intranasally.
[0111] Example 7. Study of tonsil-specific CD8+ and CD4+ T cell responses in the early protection of African swine fever virus vaccine candidates in pigs. Nine-week-old Duroc / Yorkshire crossbred pigs, 25–30 kg, negative for CSF and ASF, fed 2 kg / per animal / per day of commercial feed and water ad libitum, were assigned to experimental groups that were immunized intramuscularly with different antigens adjuvanted in oily Montanide in a 60 / 40 (v / v; aqueous / oily) ratio. All procedures were performed according to the guidelines for the use of laboratory animals.
[0112] Group 1 (3 animals): Non-immunized controls
[0113] Group 2 (3 animals): Immunized with a dose of 50 .g / 1 mL of the p72t-CD154 protein.
[0114] Group 3 (3 animals): Immunized with a dose of 50 µg / 1 mL of the p72 protein. Group 4 (3 animals): Immunized with a dose of 25 µg / 1 mL of each of the chimeric proteins p72t-CD154 and p30-CD154 adjuvanted in the same vaccine preparation.
[0115] Group 5 (3 animals): Immunized with a dose of 50 pg / 1 mL of the p7243o-CD154 protein.
[0116] Group 6 (3 animals): Immunized with a dose of 50 pg / 1 ml of the chimeric protein P7243OB6O2LLCD154.
[0117] Group 7 (3 animals): Immunized with a dose of 50 pg / 1 ml of the chimeric protein p7243oB6O2LcCD154.
[0118] Five days after immunization, the pigs were sacrificed, and the tonsils were immediately processed by maceration through a 40 µm filter with Hank's balanced salt solution. The resulting cell suspension was subjected to a density gradient by centrifugation at 400 g for 20 min with Ficoll-Paque (Amersham Bioscience). Mononuclear cells were collected, washed, and seeded in triplicate at a final concentration of 2 x 10. 6cells / mL in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 pg / ml streptomycin, 100 U / ml penicillin, 2 mM L-glutamine and 50 pM 2-mercaptoethanol and stimulated with ASFV-G, the mitogen Con A as a positive control and unstimulated. At 48 hours of stimulation, CD4+ and CD8+ T cells from each sample were selected in a flow cytometer using specific monoclonal antibodies. From these cells, total RNA was purified from which complementary DNA was synthesized that was used to study the expression of IFN y, TNFa, IL 2 and CD107a by real-time PCR in CD8+ and CD4+ lymphocytes. The relative expression of these cytokines was calculated by the 2 method ( ' ACT) , using actin as the reference gene. Group means were compared by ANOVA followed by Turkey's multiple comparisons test using Prism statistical software, version 9.0 for Windows; GraphPad Software, USA.
[0119] The results showed that CD8+ T lymphocytes from tonsils of pigs vaccinated with p72 chimeras and the combination of p72t-CD154 and p30-CD154 chimeras showed a higher expression of IFN y, IL 2 and CD107a compared to controls and those vaccinated with p72 alone. Likewise, there were statistically significant differences in the expression of IFN y and CD107a between the group vaccinated with the combination of chimeras and those vaccinated only with the p72 chimera. There were no differences in the expression of TNFoc (Figure 21 ).
[0120] In the case of CD4+ T lymphocytes from tonsils of pigs vaccinated with the p72 chimeras and the combination of the p72t-CD154 and p30-CD154 chimeras only showed a statistically significant higher expression of IFN y and IL 2 with respect to the controls and those vaccinated with p72 alone and there were only statistically significant differences in the expression of IFN y between the group vaccinated with the combination of chimeras and those vaccinated only with the p72 chimeras. In this case there were no differences in the expression of TNFoc and CD107a between the experimental groups.
[0121] These results demonstrate that the early horizontal total protection of pigs against ASFV infection and the inhibition of ASFV transmission from mothers to fetuses observed in animals vaccinated with p72 fragments fused to the extracellular fragment of CD154 and its combination with the p30-CD154 chimera could be supported by the significant specific stimulation of CD8+ and CD4+ T cells to produce IFN and IL-2 and, in the case of CD8+ cells, also CD107a. This stimulation is mediated by the presence of CD154 since it was not observed in animals immunized with p72 alone. Considering the reports in the literature that confer a transcendental importance to the stimulation of CD8+ T lymphocytes for protection against ASFV, these results demonstrate that the chimeric antigens shown here for the first time are capable of stimulating this response and are able to confer clinical and virological protection against African swine fever.CD8+ T cells are known to be a key component of adaptive immunity, contributing to the elimination of intracellular pathogens and also assisting B cells in the production of immunoglobulins.
Claims
CLAIMS 1. Chimeric antigen consisting of SEQ ID NO:3 or SEQ ID NO:8 for the protection of pigs against infection by different genotypes of African Swine Fever Virus (ASFV) comprising a conserved sequence fragment between amino acids 1 to 324 of the viral protein p72 consisting of SEQ ID NO:1 or a fragment between amino acids 1 to 430 consisting of SEQ ID NO:7 fused to the extracellular segment of CD154 of pigs consisting of SEQ ID NO:
2.
2. Chimeric antigen consisting of SEQ ID NO:11 or SEQ ID NO:12 for the protection of pigs against infection with different genotypes of the African Swine Fever Virus (ASFV) comprising a conserved sequence fragment between amino acids 1 to 430 of the viral protein p72 consisting of SEQ ID NO:7 fused to a fragment of the chaperone protein B602L of the same virus comprised between amino acids 384 to 538 consisting of SEQ ID NO:9 or 398 to 465 consisting of SEQ ID NO. 10 fused to the extracellular segment of CD154 of pigs consisting of SEQ ID NO:
2.
3. An injectable pharmaceutical composition containing the chimeric antigen of SEQ ID NO: 3 or SEQ ID NO: 8 or SEQ ID NO: 11 or SEQ ID NO: 12 according to claims 1 and 2 in a concentration of 50 g prepared with an oily Montanide adjuvant in a 60 / 40 v / v ratio.
4. The injectable pharmaceutical composition containing the chimeric antigen of SEQ ID NO: 3 according to claim 1 combined with the p30 protein of ASFV consisting of SEQ ID NO: 5 to stimulate the humoral and cellular response against ASFV and enhance the protective effect against the virus.
5. The injectable pharmaceutical composition containing the chimeric antigen of SEQ ID NO: 3 combined with the ASFV p30 protein consisting of SEQ ID NO: 5 according to claim 4 in a concentration of 25 .g of each antigen prepared with an oily Montanide adjuvant in a 60 / 40 v / v ratio.
6. The injectable pharmaceutical composition containing the chimeric antigen of SEQ ID NO: 3 according to claim 1 combined with a chimera consisting of p30 fused to the extracellular segment of CD154 of pigs consisting of SEQ ID NO: 6 that enhances the humoral and cellular response against ASFV at a concentration of 15 to 50 µg of each antigen prepared with an oily Montanide adjuvant in a 60 / 40 v / v ratio.
7. The vaccine composition according to claims 1 to 6, characterized by generating an early cellular immune response with a significant increase in CD8+ and CD4+ T lymphocytes that produce gamma interferon and IL-2.
8. The vaccine composition according to claims 1 to 6, characterized by generating an early cellular immune response with a significant increase in CD8+ T lymphocytes that produce CD107a.
9. The vaccine composition according to claims 1 to 6, characterized by generating a sterilizing immune response and inhibiting horizontal and vertical transmission of ASFV.
10. Use of a chimeric antigen consisting of SEQ ID NO:3 or SEQ ID NO:8 or SEQ ID NO:11 or SEQ ID NO:12 according to claims 1 and 2 for the manufacture of a medicament for the protection of pigs against infection by different genotypes of the African Swine Fever Virus (ASFV).
11. The use of claim 9 wherein the chimeric antigen consisting of SEQ ID NO:3 is combined with the p30 protein of ASFV consisting of SEQ ID NO:5 or a chimera consisting of p30 fused to the extracellular segment of CD154 of pigs of SEQ ID NO:6 for the manufacture of a medicament to stimulate the humoral and cellular response against ASFV and enhance the protective effect against the virus.
12. Method to stimulate the humoral and cellular response against ASFV and enhance the protective effect against ASF, characterized in that an effective amount of the chimeric antigen consisting of SEQ ID NO:3 or SEQ ID NO:8 or SEQ ID NO: 11 or SEQ ID NO: 12 is applied.
13. Method according to claim 10 wherein 50 .g of the chimeric antigen consisting of SEQ ID NO:3 or SEQ ID NO:8 or SEQ ID NO: 11 or SEQ ID NO: 12 diluted in an oily Montanide adjuvant in a 60 / 40 v / v ratio is administered.
14. The method according to claim 11 wherein the chimeric antigen consisting of SEQ ID NO:3 is combined with the p30 protein of ASFV consisting of SEQ ID NO:5 or a chimera consisting of p30 fused to the extracellular segment of CD154 of pigs of SEQ ID NO:6 to stimulate the humoral and cellular response against ASFV and enhance the protective effect against the virus.
15. Method according to claim 11, characterized in that a range between 15 and 50 .g of the combination of chimeric antigens consisting of SEQ ID NO:3 and SEQ ID NO:6 diluted in an oily Montanide adjuvant in a 60 / 40 v / v ratio is administered.
Citation Information
Patent Citations
African swine fever immune antigen and preparation method therefor and application of African swine fever immune antigen
CN111363016A
Recombinant adenovirus vector for expressing African swine fever virus p72 and B602L proteins, recombinant adenovirus and construction method
CN111549040A
Recombinant African swine fever virus p72 subunit protein, and preparation method and application thereof
CN113735943A
Chimeric vaccine antigens against classical swine fever virus
US20090304633A1
African swine fever virus vaccine
US20220047694A1
